STING1 and neoplasm: Therefore, NCP offers a strategy to overcome the limitations of the EPR effect and thus improve tumor-targeting of chemotherapeutics and STING agonists by stabilizing the drugs, improving their PK, and preferentially targeting antigen-presenting cells (APCs).